Evidence map›Paper›PMID 35453185›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation.

Cristina Sanches, Geisa C S Alves, Andras Farkas, Samuel Dutra da Silva, Whocely Victor de Castro, Farah Maria Drummond Chequer, Francisco Beraldi-Magalhães, Igor Rafael Dos Santos Magalhães, André de Oliveira Baldoni, Mark D Chatfield and 3 more

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Cristina SanchesCampus Centro Oeste, Universidade Federal de Sao Joao del Rei, Divinopolis 35501-296, Brazil.ORCID 0000-0002-8562-1337
Geisa C S AlvesCampus Centro Oeste, Universidade Federal de Sao Joao del Rei, Divinopolis 35501-296, Brazil.
Andras FarkasOptimum Dosing Strategies, Bloomingdale, NJ 07403, USA.
Samuel Dutra da SilvaCampus Centro Oeste, Universidade Federal de Sao Joao del Rei, Divinopolis 35501-296, Brazil.
Whocely Victor de CastroCampus Centro Oeste, Universidade Federal de Sao Joao del Rei, Divinopolis 35501-296, Brazil.
Farah Maria Drummond ChequerCampus Centro Oeste, Universidade Federal de Sao Joao del Rei, Divinopolis 35501-296, Brazil.ORCID 0000-0003-3514-2132
Francisco Beraldi-MagalhãesPrograma de Pós Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus 69040-000, Brazil.ORCID 0000-0002-0944-3321
Igor Rafael Dos Santos MagalhãesFaculdade de Ciências Farmacêuticas, Universidade Federal do Amazonas, Manaus 69077-000, Brazil.ORCID 0000-0002-0651-696X
André de Oliveira BaldoniCampus Centro Oeste, Universidade Federal de Sao Joao del Rei, Divinopolis 35501-296, Brazil.ORCID 0000-0001-6379-0415
Mark D ChatfieldUniversity of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, QLD 4029, Australia.
Jeffrey LipmanUniversity of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, QLD 4029, Australia.ORCID 0000-0002-5965-9876
Jason A RobertsUniversity of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, QLD 4029, Australia.ORCID 0000-0001-6218-435X
Suzanne L ParkerUniversity of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, QLD 4029, Australia.ORCID 0000-0002-6124-7475
Federal University of São João del-Rei · BRThe University of Queensland · AUOptimum Technologies (United States) · USUniversidade do Estado do Amazonas · BRUniversidade Federal do Amazonas · BR

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-00855-19National Council for Scientific and Technological Development 428671/2018-7
6 · The paper itself

Abstract

Objectives: This study aimed to develop a piperacillin population PK model for critically ill Brazil-ian patients and describe interethnic variation using an external validation. Methods: Plasma samples were obtained from 24 ICU patients during the fifth day of piperacillin treatment and assayed by HPLC-UV. Population pharmacokinetic modelling was conducted using Pmetrics. Empiric dose of 4 g IV 6- and 8-hourly were simulated for 50 and 100% fT > MIC and the probabil-ity of target attainment (PTA) and the fractional target attainment (FTA) determined. Results: A two-compartment model was designed to describe the pharmacokinetics of critically ill Brazillian patients. Clearance and volume of distribution were (mean ± SD) 3.33 ± 1.24 L h−1 and 10.69 ± 4.50 L, respectively. Creatinine clearance was positively correlated with piperacillin clearance and a high creatinine clearance was associated with lower values of PTA and FTA. An external vali-dation was performed using data from two different ethnic ICU populations (n = 30), resulting in acceptable bias and precision. Conclusion: The primary pharmacokinetic parameters obtained from critically ill Brazilian patients were similar to those observed in studies performed in critically ill patients of other ethnicities. Based on our results, the use of dose adjustment based on creati-nine clearance is required in Brazilian patients.

Indexed as

antimicrobialcritically illethnic grouppharmacokineticspiperacillin

Identifiers

PMID35453185
PMCPMC9029174
OpenAlexW4221105076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.